Skip to main content

Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that management will participate in one-on-one meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day. The conference is being held in a virtual format on Tuesday, May 3rd, 2022.

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is currently under investigation in a Phase 1 single agent multicenter clinical trial in patients with advanced solid tumors To date, TTI-101 has been well tolerated and demonstrated multiple durable radiographic objective responses in patients treated with TTI-101 monotherapy. To learn more, please visit https://tvarditherapeutics.com/

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.37
-2.00 (-0.78%)
AAPL  349.47
+0.26 (0.07%)
AMD  449.62
-39.57 (-8.09%)
BAC  48.35
-0.22 (-0.44%)
GOOG  274.88
+3.86 (1.42%)
META  576.47
-19.75 (-3.31%)
MSFT  495.39
-2.91 (-0.58%)
NVDA  137.76
-8.22 (-5.63%)
ORCL  105.32
-5.25 (-4.75%)
TSLA  362.68
-11.73 (-3.13%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.